New Retina Radio is a place to hear stories about retina that are told nowhere else.
View full description +
Subscribe
08.18.26
The Story Behind LYTENAVA™: From FDA Approval to Retina PracticeIn this episode of New Retina Radio, host Barry Kuppermann, MD, PhD, sits down with Bob Jahr, CEO of Outlook Therapeutics, to discuss the FDA approval of LYTENAVA™ (bevacizumab-vikg), the only FDA-approved ophthalmic bevacizumab formulation for nAMD.1,2 They explore the regulatory journey over the course of more than 8 years,3 the rigorous FDA review process,4 manufacturing and product quality, commercialization plans, payer considerations, and future development. Please see the Important Safety Information and full US Prescribing Information for LYTENAVA.
Intended for a US audience only.
Sponsored by Outlook Therapeutics
References
1. Harp MD. FDA approves Outlook Therapeutics' LYTENAVA for the treatment of wet AMD. Ophthalmology Times. Published July 24, 2026. Accessed July 28, 2026. https://www.ophthalmologytimes.com/view/fda-approves-outlook-therapeutics-lytenava-for-the-treatment-of-wet-amd
2. LYTENAVA™ (bevacizumab-vikg) prescribing information. Outlook Therapeutics; 2026.
3. Outlook Therapeutics. Oncobiologics changes name to Outlook Therapeutics; announces next steps in executing ONS-5010 clinical and regulatory strategy. Published December 3, 2018. Accessed July 24, 2026. https://ir.outlooktherapeutics.com/news-releases/news-release-details/oncobiologics-changes-name-outlook-therapeutics-announces-next
4. US Food and Drug Administration. The FDA's drug review process: ensuring drugs are safe and effective. Updated January 4, 2018. Accessed July 28, 2026. https://www.fda.gov/drugs/information-consumers-and-patients-drugs/fdas-drug-review-process-ensuring-drugs-are-safe-and-effective
08.12.26
The Fellow Eye: Episode 6Justin C. Muste, MD; David Fell, MD; Monia Reding, MD; and Benjamin Young, MD
Editorially Independent
08.05.26
ASRS '26: SOL-1 and TRUCKEE at 4.5 YearsDilsher Dhoot, MD; and Carl Danzig, MD
Editorially independent content, supported by Genentech.
07.16.26
New Retina Radio Journal Club w/ VBS: Clinical Features and Outcomes of IOFB RemovalJordan Deaner, MD; Vaidehi Dedania, MD; and Rehan Hussain, MD
Editorially Independent Content Supported by Genentech
07.08.26
Barriers to Care, Patient Education, and Treatment Decisions in Geographic AtrophyGeeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD
Editorially independent content, supported by Astellas & Zeiss
07.08.26
Evolving Practice Patterns and Dosing Strategies in Geographic AtrophyGeeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD
Editorially independent content, supported by Astellas & Zeiss
07.08.26
Biomarkers, Imaging, and Early Treatment Decisions in Geographic AtrophyGeeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD
Editorially independent content, supported by Astellas & Zeiss
07.01.26
The Fellow Eye: Episode 5Justin C. Muste, MD; David Fell, MD; Omesh P. Gupta, MD; and Shane Griffin, MD, MCR
06.26.26
Retinal Perfusion, Sensitivity, and Function in DRBarton Blackorby, MD; Katherine Talcott, MD; and Hong-Uyen Hua, MD
Editorially Independent Content Supported by Genentech
Show More